SHARE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项旨在帮助艾滋病研究工作的研究(SHARE)是由NIAID和NCI于1983年资助的，目的是研究人类免疫缺陷病毒1型(HIV)感染的自然历史。Share与芝加哥、匹兹堡和洛杉矶的类似网站一起组成了多中心艾滋病队列研究(MACS)。MACS参与者，包括1447名注册了SHARE的人，自1984年以来每半年进行一次跟踪，并提供了问卷数据、体检数据、实验室数据(包括艾滋病毒血清和T细胞亚群测量)以及大量血浆、血清、冷冻保存的外周血单核细胞和其他标本。评估和跟踪SHARE和MACS中艾滋病毒感染的流行和事件病例，为以下方面提供了关键的见解：艾滋病毒-1感染的风险因素、艾滋病毒感染一旦确立、艾滋病毒感染的宿主防御、影响艾滋病毒发病的遗传因素、以及针对艾滋病毒感染和机会性病原体的不同治疗方法的使用和疗效。Share和Mac刚刚完成了1326名额外参与者的招募，其中包括352名Share，他们比之前招募的队列更年轻，更不是高加索人。具体目标包括：确定高效抗逆转录病毒疗法(HAART)的长期有效性；确定HAART个人反应的决定因素，包括宿主遗传特征、合并感染(肝炎病毒，HHV-8)、对艾滋病毒的免疫反应、依从性、种族/族裔；确定宿主对艾滋病毒感染的抵抗和感染进展的机制；并作为独立资助的病因学研究和其他合作研究的平台，包括艾滋病毒-1致病机理的病毒学和免疫学机制、疾病进展或不进展的实验室相关性，以及联合感染与艾滋病毒之间的生物相互作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Study to Help the AIDS Research Effort (SHARE) was funded by NIAID and NCI in 1983 to study the natural history of infection with human immunodeficiency virus, type 1 (HIV). SHARE, along with similar sites in Chicago, Pittsburgh, and Los Angeles, forms the Multicenter AIDS Cohort Study (MACS). MACS participants, including 1447 enrolled in SHARE, have been followed semiannually since 1984 and have provided questionnaire data, physical exam data, laboratory data (including HIV serostatus and T cell subset measurements), and a large repository of plasma, serum, cryopreserved peripheral blood mononuclear cells and other specimens. Evaluating and following the prevalent and incident cases of HIV-infection in SHARE and the MACS, has provided key insights into risk factors for infection with HIV-1, monitoring and mechanisms of progression of HIV infection once it is established, host defense against HIV, genetic factors affecting HIV pathogenesis, and use and efficacy of different therapies for HIV infection and for opportunistic pathogens. SHARE and MACS have just completed the recruitment of 1326 additional participants, including 352 in SHARE, who are younger and more non-caucasian than the cohort previously recruited. Specific Aims include: determine the long-term effectiveness of highly active antiretroviral therarpy (HAART); define determinants of individual responses to HAART including host genetic characteristics, co-infections (hepatitis viruses, HHV-8), immune responses to HIV, adherence, race/ethnicity; define mechanisms of host resistance to HIV infection and progression of the infection; and serve as a platform for independently funded pathogenesis studies and other collaborative research, including virological and immunological mechanisms of HIV-1 pathogenesis, laboratory correlates of disease progression or non-progression, and biological interactions between co-infections and HIV.